Momenta names Craig Wheeler as its new chief executive officer

By Lisa Kerner

Charlotte, N.C., Aug. 22 - Momenta Pharmaceuticals, Inc. named Craig A. Wheeler as the company's new chief executive officer.

Wheeler, who will assume CEO duties beginning Sept. 12, has also been elected to Momenta's board of directors, according to a company news release.

Momenta's new CEO succeeds Alan Crane, who remains a member of the board of directors.

Previously, Wheeler served as president of Chiron BioPharmaceuticals, the biotechnology division of Chiron Corp., overseeing the acquisitions of Matrix Pharmaceuticals and Sagres Discovery.

Prior to joining Chiron, Wheeler was a partner at The Boston Consulting Group.

Momenta said Wheeler will continue to serve as a director for Avanir Pharmaceuticals and as a member of the IBM Life Sciences Strategic Advisory Council.

Momenta is a Cambridge, Mass., biotechnology company specializing in the characterization and engineering of complex drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.